STRATEC SE — Investor Presentation 2016

Jul 21, 2016

H1 2016 Financial Results

as of June 30, 2016

Conference Call July 21, 2016

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forwardlooking statements are realistic, we can provide no guarantee of this.

This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

• 1. Highlights of the first six months of 2016
• 1. Financials
• 1. Acquisitions
• 1. Outlook & Focus

Highlights 6M/2016

• Two major company acquisitions successfully executed

Consolidated as of April1, 2016 Consolidated as of July 1, 2016

Budapest, Hungary Anif near Salzburg, Austria ~ 230 employees ~ 130 employees

Former Sony DADC BioSciences

• ~ € 34 million sales in 2015 ~ € 14 million sales 2015/16

Highlights 6M/2016

• Revenues increased by 11.5% to € 78.0 million
• Rising EBIT margin in Q2
• Dividend pay out after AGM in June 2016 of € 0.75 per share (2015: € 0.70)
• Number of employees: 606 +7.8% organic June 30, 2016 (6M/2015: 562)

842 including Diatron

• ~ 960 Total as of July, 2016 (incl. Stratec Consumables)

• Several new programs in pipeline

• 1. Highlights of the first six months of 2016
• 1. Financials
• 1. Acquisitions
• 1. Outlook & Focus

FINANCIALS AT A GLANCE

Key figures after the first six months

(€ million)	June 30, 2016	June 30, 2015	Change
Sales	78.0	70.0	+ 11.5%
EBIT	12.61	12.0	+ 5.3%
EBIT margin (%)	16.21	17.1	- 95 bps
Cons. net income	10.32	9.8	+ 5.1%
Earnings per share (€)	0.872	0.83	+ 4.6%

¹ 2016 figure adjusted to exclude non-recurring items for transaction activities

² 2016 figure additionally adjusted to exclude financing expenses and tax expenses in connection with the acquisition of the Diatron Group and non-recurring items arising from the external tax audit for the assessment periods from 2009 to 2013.

Adjustments as of June 30, 2016

in $\epsilon$ thousand	01.01.-06.30.2016
Adjusted consolidated net income	10,372
Adjustments
Expenses due to company acquisitions	$-985$
Internal integration expenses	$-218$
Realization of hidden reserves identified	$-263$
Expenses due to purchase price allocation	$-1,199$
Financing expenses due to company acquisitions and external tax audit	$-397$
Current tax expenses	$-1,052$
Deferred tax expenses	201
Consolidated net income	6,399
Earnings per share $(\epsilon)$	0.54

in $\epsilon$ thousand	$01.01 - 06.30.2016$
Adjusted EBIT	12,616
Adjustments
Expenses due to company acquisitions	$-985$
Internal integration expenses	$-218$
Expenses due to purchase price allocation	$-1,199$
Realization of hidden reserves identified	$-263$
FRIT	9.951

SALES

6-Months Sales compared to Annual Sales

6M/2016 Sales

• +11.5% to € 78.0 Mio.
• Diatron: €10.5 Mio. in Q2

Q2/2016 Sales organically

• +2.6% to € 36.3 Mio. (Q2/2015: € 35.5 Mio.)

EBIT & EBIT MARGIN

As of June 30

EBIT margin picking up:

• Reinstating economies of scale in Q2
• Q2/2016 (organic): 17.49% +16 bps (Q2/2015:17.33%)
• 6M/2016: 16.17% / 95 bps (6m/2015: 17.12%)

¹ figures exclude non-recurring special effects

EARNINGS AFTER SIX MONTHS

0.63 0.56 0.82 0,83 0,00 0,10 0,20 0,30 0,40 0,50 0,60 0,70 0,80 0,90 1,00 2012 2013 2014 2015 2016 EPS 0,88

Earnings per share as of June 30

• Adjusted EPS at € 0.87 (6M/2015: € 0.83)
• Adjusted 6M tax rate at 15.9% (6M/2015: 19.2%)
• Dividend pay out per share at € 0.75

(previous year: € 0.70)

1 figures exclude non-recurring special effects

€

• 1. Highlights of the first six months of 2016
• 1. Financials
• 1. Acquisitions
• 1. Outlook & Focus

DIATRON – EXPANDING THE VALUE CHAIN

DIATRON PRODUCTS

EXPANDING THE LAB AUTOMATION VALUE CHAIN

PRODUCT EXAMPLES STRATEC Consumables

• 1. Highlights of the first six months of 2016
• 1. Financials
• 1. Acquisitions
• 1. Outlook & Focus

STRATEC – FINANCIAL GUIDANCE

	FY 2016	FY 2017
Revenues	175 – 182 € million	205 – 220 € million
EBIT-Margin	16.0 % - 17.5 %	Slight growth compared to 2016

Organic growth (excluding Diatron and STRATEC Consumables acquisitions): CAGR ~6 % for 2016 and 2017

Focus in 2016 and beyond

• Post merger integration process
• Expanding role as developer and manufacturer of instruments, consumables and software
• Significant synergies through joint development & production
• Reduction of integration risk withing projects for partners
• Achieve milestones & market launches

STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Tel: +49 7082 7916-0 Fax: +49 7082 7916-999 www.stratec.com

Marcus Wolfinger CEO m.wolfinger@stratec.com

TICKER
Symbol:	SBS.DE
Bloomberg:	SBS:GR
Reuters:	SBSG.DE
ISIN:	DE0007289001
WKN:	728900

THANK YOU FOR YOUR ATTENTION!